[ad_1]
Ultimovacs ASA (“Ultimovacs”, stock code ULTI), a pharmaceutical company that develops new immunotherapies for cancer, today announced its results for the first quarter of 2021. The speech of the company’s management team will be conducted via webcast at 09:00 CEST today.The demo can be used as a live, Can also be found on our website.
Highlights of the first quarter of 2021:
-
In the INITIUM trial, 40 patients have been recruited as of the reporting date, compared to 24 patients reported in the previous quarterly report.
-
In the NIPU trial, 29 patients had been recruited as of the reporting date, compared with 18 patients reported in the previous quarterly report.
-
Due to the natural consequences of the COVID-19 pandemic, the hospital’s start-up schedule was slower than originally planned in the INITIUM and NIPU trials. The company will continue to carry out activities to minimize the impact on patient recruitment. The impact of the pandemic on the biotechnology industry and the general ability to conduct clinical trials is still uncertain and depends on the speed of recovery to more normal conditions.
-
Ultimovacs will provide details of the DOVACC trial in January 2021. Ultimovacs will participate in this randomized phase II collaborative study with the Clinical Trials Unit of the Nordic Society of Gynecological Oncology (NSGO-CTU) and the European Network of European Gynecological Oncology Trials (ENGOT). ) And AstraZeneca to evaluate Ultimovacs’ proprietary universal cancer vaccine UV1 in combination with AstraZeneca’s durvalumab and olaparib in the treatment of patients with recurrent ovarian cancer. The trial will enroll 184 patients in more than 40 locations in approximately 10 European countries. (Announced in the fourth quarter report of 20 years).
-
Preparations are being made for the launch of the DOVACC and FOCUS trials, and it is expected that the first batch of patients will participate in both trials at the same time around mid-2021.
-
On February 18, 2021, Ultimovacs began clinical evaluation of the new TET platform and studied the first patient to study a prostate cancer-specific vaccine in the TENDU Phase I study. As of the report date, the first three patients have been recruited.
-
On April 28, 2021, Ultimovacs announced that the company’s phase I trial abstract in evaluating the combination of its universal cancer vaccine UV1 and the checkpoint inhibitor pembrolizumab for the treatment of patients with metastatic malignant melanoma has been accepted for poster presentation at the American Academy of Clinical Medicine . The 2021 Oncology (ASCO) Annual Conference (post-event) to be held from June 4 to 8, 2021.
-
In Q1-21, the total operating expenditure is MNOK 31.2.
-
Operating cash flow for the first quarter 1-21 was MNOK -29.5. As of March 31, 2021, the total amount of cash and cash equivalents is 409.3 MNOK.
Reports and presentations are also available in Company website.
For more information, please visit www.ultimovacs.com Or contact:
View the source code version on businesswire.com: https://www.businesswire.com/news/home/20210510005617/zh/
[ad_2]
Source link
